Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Zacks News
Merck (MRK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q1 earnings.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $114.13, marking a -0.61% move from the previous day.
Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates
by Zacks Equity Research
Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector.
Company News for Apr 18, 2023
by Zacks Equity Research
Companies in The News Are: MTB,RXDX,NFLX,ANET,MRK
Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence
by Zacks Equity Research
Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candidate reduces the risk of recurrence/death.
Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck
by Zacks Equity Research
Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio. Prometheus' stock is up 70%.
Top Analyst Reports for Eli Lilly, Thermo Fisher Scientific & Lockheed Martin
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO) and Lockheed Martin Corporation (LMT).
Merck's (MRK) Keytruda sBLA Accepted by FDA for Gastric Cancer
by Zacks Equity Research
Merck's (MRK) application seeking approval for Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy for the early treatment of locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was accepted by the FDA.
Pharma Stock Roundup: FDA Rejects LLY's Mirikizumab, NVO Ups 2023 Sales & Profit View
by Kinjel Shah
FDA issues CRL to Eli Lilly's (LLY) BLA seeking approval of mirikizumab for ulcerative colitis (UC). Novo Nordisk (NVO) ups sales and profit outlook for 2023.
Markets Rally on Cooler Economic Data; More Results on Deck
by Mark Vickery
Weaker economic prints are beginning to reveal an alternative narrative: perhaps the Fed has done enough already.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $115.58, moving +1.61% from the previous trading session.
Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy
by Zacks Equity Research
Fusion (FUSN) surges after investigational new drug application clearance by the FDA for its targeted alpha therapy FPI-2068, co-developed with AstraZeneca.
Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag
by Zacks Equity Research
The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer
by Zacks Equity Research
J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog.
Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail
by Zacks Equity Research
Merck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals.
Zacks Investment Ideas feature highlights: Nvidia, United Healthcare, Merck, Pfizer and Intuitive Surgical
by Zacks Equity Research
Nvidia, United Healthcare, Merck, Pfizer and Intuitive Surgical are part of the Zacks Investment Ideas article.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Will Bristol Myers (BMY) Gain From New Drugs' Label Expansion?
by Zacks Equity Research
Label expansion of Bristol Myers' (BMY) new drugs should help it somewhat combat the decline in Revlimid sales due to generic competition.
Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates
by Kinjel Shah
J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.
3 Reasons to Buy Healthcare Stocks in the Current Market Environment
by Andrew Rocco
Healthcare stocks are currently providing investors with an attractive way to counterbalance a portfolio overexposed to tech. In general, healthcare stocks have lower betas, are more defensive, and have cleaner balance sheets.